Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy-Reference-Cited by-同舟云学术

Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy

Published:2018-12-22 Issue:1 Volume:69 Page:376-393
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Ardelt Maximilian A.¹²,Fröhlich Thomas³,Martini Emanuele⁴,Müller Martin¹,Kanitz Veronika⁵,Atzberger Carina¹,Cantonati Petra²,Meßner Martina¹²,Posselt Laura⁶,Lehr Thorsten⁷,Wojtyniak Jan-Georg⁷,Ulrich Melanie¹,Arnold Georg J.³,König Lars⁶,Parazzoli Dario⁴,Zahler Stefan¹,Rothenfußer Simon⁶,Mayr Doris⁵,Gerbes Alexander⁸,Scita Giorgio⁴,Vollmar Angelika M.¹,Pachmayr Johanna¹²

Affiliation:

1. Department of Pharmacy, Pharmaceutical Biology; LMU Munich; Munich Germany

2. Institute of Pharmacy; Paracelsus Medical University; Salzburg Austria

3. Laboratory for Functional Genome Analysis, LAFUGA, Gene Centre; University of Munich; Munich Germany

4. IFOM-FIRC Institute of Molecular Oncology; Department of Oncology and Hemato-Oncology; University of Milan; Milan Italy Milan Italy

5. Institute of Pathology; Ludwig Maximilians University of Munich; Munich Germany

6. Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Internal Medicine IV; Klinikum der Universität München; Munich Germany

7. Clinical Pharmacy; Saarland University; Saarbrücken Germany

8. Department of Medicine 2, Liver Center Munich; University Hospital, LMU Munich; Munich Germany

Funder

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.30190/fullpdf

Reference49 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011